DGAP-News: ClariVein(R) Dose Finding Trial
(firmenpresse) - Vascular Insights LLC
31.08.2012 09:00
---------------------------------------------------------------------------
MADISON, Conn., 2012-08-31 09:00 CEST (GLOBE NEWSWIRE) --
Vascular Insights LLC announced the start of a multi center dose-finding study
conducted by principal investigator Professor Cees Wittens MD, PhD and Yee Lai
Lam MD Maastricht University Medical Center, Maastricht, The Netherlands.
The ClariVein(r) dose-finding study is a randomized controlled trial, which will
be conducted in the Maastricht university hospital and 7 additional centers in
the Netherlands.
The objective of the study is to identify the ideal sclerosant dosage for great
saphenous vein (GSV) occlusion using the ClariVein(r) system.
'We are confident and excited that this study will demonstrate once again that
ClariVein(r) is the most innovative and safe form of treatment for varicose veins
and venous reflux,' said John P. Marano, President of Vascular Insights.
'This study shows Vascular Insights' continuing commitment to ensuring the most
effective patient outcomes when using the ClariVein(r) system. We continue to
make significant investments in research to generate the data that once again
proves the effectiveness of ClariVein(r).', said Marano.
600 patients will be included in the study. Patients (CEAP classification
C2-C4) who are first time treated for incompetence of the GSV, proven with
duplex ultrasound examination.
Professor Wittens stated, 'Because the ClariVein(r) method allows safe treatment
of venous segments along nerves, we may significantly improve the optimal
treatment of GSV and small saphenous vein (SSV) incompetence by extending the
treatment length beyond the traditional approach.'
The ClariVein(r) catheter is a product of Vascular Insights LLC
(http://vascularinsights.com) of Madison, Connecticut USA. The company engages
in the design, development, manufacture, and marketing of medical devices for
the minimally invasive treatment of peripheral vascular disease.
The Vascular Insights LLC logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=13814
CONTACT: Joseph Mullally
Director of International Sales
Vascular Insights LLC
jmullally(at)vascularinsights.com
203 446 5709
News Source: NASDAQ OMX
31.08.2012 Dissemination of a Corporate News, transmitted by DGAP -
a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: Vascular Insights LLC
United States
Phone:
Fax:
E-mail:
Internet:
ISIN: US9901942279
WKN:
End of Announcement DGAP News-Service
---------------------------------------------------------------------------
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 31.08.2012 - 09:00 Uhr
Sprache: Deutsch
News-ID 179384
Anzahl Zeichen: 6518
contact information:
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 302 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DGAP-News: ClariVein(R) Dose Finding Trial"
steht unter der journalistisch-redaktionellen Verantwortung von
Vascular Insights LLC (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
